American Health Council Names Mark R. Kelley, PhD to Education Board

New York, New York – Dr. Mark R. Kelley, Betty and Earl Herr Professor of Pediatric Oncology Research/ Professor of Pediatrics, Biochemistry and Molecular Biology & Pharmacology and Toxicology at the Indiana University School of Medicine has been selected to join the Education Board at the American Health Council. He will be sharing his knowledge and expertise on Redox Signaling Biology, DNA repair and Cancer … Read more…

Apexian Pharmaceuticals Announces FDA Acceptance of Phase 1 Protocol to Include Biomarker Measurements and Evaluate the Tolerability and Anti-Tumor Effects of APX3330

Indianapolis, IN  – Apexian Pharmaceuticals, a clinical stage biotechnology company developing novel compounds to treat cancer, today announced that it has received FDA authorization to initiate the Phase 1 study of its lead compound APX3330, an inhibitor of the APE1 protein. APE1, when found at high levels in patients with advanced cancer, correlates with decreased overall survival. Leveraging the wealth of pre-clinical data that has … Read more…